Top Markets
Coin of the day
Albireo Pharma, Inc. Albireo Pharma, Inc.

Albireo Pharma, Inc.

ALBO
株式のランク #12829
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products,... Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
株価
$44.15
最終同期: 2023-03-02
時価総額
$545.52M
変化(1日)
-0.23%
変化(1年)
0.00%
US
取引 Albireo Pharma, Inc. (ALBO)

カテゴリー

Albireo Pharma, Inc.(ALBO)の配当利回りの履歴
Albireo Pharma, Inc.(銘柄コード: ALBO)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Albireo Pharma, Inc.(ALBO)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)